Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

(Reuters) -Novavax beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to ...

Wondering if Novavax is a hidden bargain or just another biotech roller coaster? You are not alone, and getting to the bottom of its real value is more important than ever. Despite plenty of buzz, ...

Novavax raised its full-year 2025 revenue framework, now expecting adjusted total revenue between $1.04 billion and $1.06 ...

Novavax (NVAX) stock in focus as the company boosts 2025 revenue outlook after better than expected Q3 revenue driven by ...

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...

Analysts expect Novavax to report an earnings per share (EPS) of $-0.96. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

Shares of Novavax Inc. NVAX shed 1.94% to $7.06 Thursday, on what proved to be an all-around grim trading session for the ...

Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of ...